Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

[Background] Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The HHT wo...

Descripción completa

Detalles Bibliográficos
Autores: Buscarini, Elisabetta, Botella, Luisa María, Geisthoff, Urban, Kjeldsen, Anette D., Mager, Hans J., Pagella, Fabio, Suppressa, Patrizia, Zarrabeitia, Roberto, Dupuis-Girod, Sophie, Shovlin, Claire L.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/175650
Acceso en línea:http://hdl.handle.net/10261/175650
Access Level:acceso abierto
Palabra clave:Hereditary hemorrhagic telangiectasia
Bevacizumab
Thalidomide
Adverse events
Bleeding
Arteriovenous malformation
Epistaxis
Cardiac failure
Nosebleeds
Descripción
Sumario:[Background] Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The HHT working group within the ERN for Rare Multisystemic Vascular Diseases (VASCERN), developed a questionnaire-based retrospective capture of adverse events (AEs) classified using the Common Terminology Criteria for Adverse Events.

Similares en LA Referencia